It is some fifty years since the thalidomide disaster when several thousand children around the world were born with severe limb defects after their mothers had been given thalidomide as sedative and remedy for morning sickness.
It is some fifty years since the thalidomide disaster when several thousand children around the world were born with severe limb defects after their mothers had been given thalidomide as sedative and remedy for morning sickness.
Drugs at that time were not required to have been tested for potential effects on the fetus.
One consequence of this tragedy was a great enhancement of the processes for licensing new medicines in an attempt to assuage public anxiety that there could ever be another similar disaster; and that there was any risk at all involved in taking a licensed medicine.
Where, nevertheless, significant side effects were found it became the practice to sue for damages.
Professor Sir Peter Lachmann, Emeritus Sheila Joan Smith Professor of Immunology at Cambridge, is giving a lecture on Friday evening at the Law Faculty building on the Sidgwick site entitled The Penumbra of Thalidomide.
He will argue that these consequences have given rise to possibly an even greater disaster damaging a much larger number of people and threatening ruin to health services everywhere.
The huge increase in both the time taken and the cost involved in bringing a new medicine to market is increasing the price of many new medicines to unsupportable levels.
It has also led to the situation where only companies with deep pockets are able to take medicines to market; and even they will do so only for diseases common enough that they can envisage making a profit.
The licensing of new medicines therefore requires urgent and wide-ranging reform which will need changes to both national and European legislation.
The increasingly widespread litigation culture for “statistical” harmful effects that involve neither negligence nor other malfeasance also needs to be addressed. The damages incurred lead to a further increase in the price of medicines.
Reforms to reduce the cost of medicines would save the NHS far more than the structural changes now before Parliament. But it will no easier to bring them about.
Sir Peter was President of the Royal College of Pathologists (1990-1993); Biological Secretary of the Royal Society (1993-1998); and Founder President of the UK Academy of Medical Sciences (1998-2002). He served on UNESCO's International Bioethics Committee (1993-1998).
In these capacities he became involved in the ethical and policy controversies surrounding vaccination, stem cells, transmissible spongiform encephalopathies and genetically modified food crops.
The lecture is open to all on Friday 18 November at 5.30pm in Lecture theatre L17 at the Faculty of Law, Sidgwick Site.
This work is licensed under a Creative Commons Licence. If you use this content on your site please link back to this page.